(Finance) – Great day for Hims & Hers Health which is recording an increase of 10.33%.
Boosting stocks is news that the Food and Drug Administration will allow pharmacies to sell their own versions of Eli Lilly’s Mounjaro weight-loss drug.
The comparison of the title with theS&P-500on a weekly basis, shows the greatest relative strength of Hims & Hers Health compared to the index, highlighting the concrete attractiveness of the stock by buyers.
The medium-term structure remains positively connoted, while signs of contraction emerge for the short-term approach forced to deal with the resistance identified at USD 21.31. The functional support role offered by 19.82 is still excellent. Overall, the general context could justify a continuation of the consolidation phase towards 19.01.